The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients

Breast. 2014 Jun;23(3):264-72. doi: 10.1016/j.breast.2013.11.008. Epub 2014 Feb 12.

Abstract

The aim of the present study was to analyze the effect of subtype and body mass index (BMI) on neo-adjuvant chemotherapy (NAC) and postoperative prognosis. Two-hundred and forty nine patients who underwent surgery after NAC were included. A multivariate analysis and survival analysis were used to clarify the relationship between BMI, subtype, and NAC. In the logistic regression model, the pCR rate had a significant relationship with the subtype and tumor stage. In the non-pCR group, more overweight patients had significantly a worse disease-free survival (DFS) compared to normal range patients (Log lank test, p < 0.05). In the Cox proportional hazards model, subtype and tumor stage were significantly associated with decreased DFS. In conclusion, patients with the ER (+), HER (-) type and a high BMI had a high risk for recurrence when they achieved non-pCR after NAC.

Keywords: Body mass index; Breast neoplasms; Neoadjuvant therapy.

MeSH terms

  • Adult
  • Body Mass Index
  • Breast / pathology
  • Breast Neoplasms* / classification
  • Breast Neoplasms* / epidemiology
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / pathology
  • Breast Neoplasms* / therapy
  • Chemotherapy, Adjuvant / methods*
  • Disease-Free Survival
  • Female
  • Humans
  • Japan / epidemiology
  • Mastectomy / statistics & numerical data
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Neoplasm Recurrence, Local* / diagnosis
  • Neoplasm Recurrence, Local* / epidemiology
  • Neoplasm Staging
  • Obesity* / epidemiology
  • Prognosis
  • Proportional Hazards Models
  • Receptors, Cell Surface / analysis
  • Risk Assessment
  • Risk Factors

Substances

  • Receptors, Cell Surface